Zytoreduktive Chirurgie und hypertherme intraperitoneale Chemotherapie beim Magenkarzinom.

Background: Gastric cancer with peritoneal metastases is associated with an extremely poor prognosis. Developed multimodal treatment concepts, which include a combination of perioperative systemic treatment and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), show promising results with respect to improvement of the long-term survival. Methods: This article contains a review of the literature of published studies on the topic of gastric cancer and peritoneal metastasis. Results: The prognosis of patients with gastric cancer peritoneal carcinomatosis shows an extremely limited median survival of 7 months under palliative second-line systemic treatment. The median survival time increased to 12 months with cytoreductive surgery and in combination with HIPEC showed a positive effect on survival in individual studies. Expert opinion: Treatment recommendations for patients with peritoneal metastases of gastric cancer should be carried out by experts in surgical reference centers. [ABSTRACT FROM AUTHOR]